The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes

Cells. 2021 Jun 24;10(7):1589. doi: 10.3390/cells10071589.


Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with type 1 diabetes to withdraw from insulin therapy. However, several issues exist regarding the use of stem cell therapy to treat type 1 diabetes. In this review, we will focus on the following topics: (1) autoimmune responses during the autologous transplantation of stem cell-derived islet cells, (2) a comparison of stem cell therapy with insulin injection therapy, (3) the impact of the islet microenvironment on stem cell-derived islet cells, and (4) the cost-effectiveness of stem cell-derived islet cell transplantation. Based on these various viewpoints, we will discuss what is required to perform stem cell therapy for patients with type 1 diabetes.

Keywords: diabetes; pancreatic β-cell; stem cell therapy; type 1 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmunity
  • Cellular Microenvironment
  • Cost-Benefit Analysis
  • Diabetes Mellitus, Type 1 / economics
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / pathology
  • Diabetes Mellitus, Type 1 / therapy*
  • Feasibility Studies
  • Humans
  • Stem Cell Transplantation* / economics